cyrilzakka/clinical-trials huggingface dataset:
Functional Disorders of the Musculoskeletal System in People With Multiple Sclerosis

The randomized controlled trial is aimed to study the efficacy of treatment approaches based on developmental kinesiology models and its impact on balance, gait and mobility in people with mild to severe multiple sclerosis (pwMS). The main goal is to compare two out-patient physiotherapeutic methods, that will be attended 1-hour twice a week for one month and once a week for next two months (16 therapies in total). The efficacy will be assessed by a blinded independent clinical examiner using clinical examination and questionnaire survey one month before the therapy programme, immediately before and after the therapy and two months after termination of the therapy.

The participants were randomly divided into two groups for three-month outpatient physiotherapeutic programme.

One group obtained treatment by MFK Method (Manual physiotherapeutic correction) and the second by DNS (Dynamic Neuromuscular Stabilization ). Both treatment methods were developed in the Czech Republic. All participants attended 1-hour MFK Method or DNS twice a week for one month and once a week for next two months (16 therapies in total).

The participants were examined three times - before the start of the physiotherapy program, immediately after its completion and six months apart.

Eligibility Criteria:
Inclusion Criteria:

* exact diagnosis of MS stated by neurologist
* Expanded Disability Status Scale (EDSS) ≥ 2 and ≤ 6,5
* no previous physiotherapy in six months
* no clinical relapses and changes in pharmacotherapy in the previous month or during the rehabilitation trial
* ability to undergo ambulatory physiotherapy

Exclusion Criteria:

* other neurological disease or conditions disabling movement (e.g. stroke, pregnancy, fracture)
A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor

This study is a Phase I, open-label, single-arm clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of GK01 in patients with advanced solid tumors.


Eligibility Criteria:
1. Ability to understand and sign a written informed consent document；
2. At the date of signing ICF, 18 \~70 years old, male or female；
3. Histopathological confirmed advanced solid tumor patients who have failed to standard treatment or intolerance with standard treatment；
4. There is at least one resectable tumor lesion that has not received radiation therapy or other local therapies;
5. At least one measurable lesion at baseline per RECIST version 1.1；
6. The expected survival time is more than 12 weeks;
7. ECOG 0-1 points;
8. Adequate organ functions
Effect of Subcutaneous Polyvidone Collagen Treatment on Hand Recovery in Adult Rheumatoid Arthritis.

A study in geriatric rheumatology on the treatment of rheumatoid arthritis (RA) in older adults is described. Its objective is to compare the effects of subcutaneous polyvidone collagen versus placebo, analyzing clinical improvement, biochemical response and quality of life in people over 60 years of age.

The Phase IV, double-blind, randomized, placebo-controlled clinical trial will be conducted between 2023 and 2026. Sixty patients with early-stage arthritis will participate, assessing factors such as pain, functionality and synovitis with various statistical tools and analyses.

Geriatric rheumatology specializes in the study of rheumatic diseases in older adults, who have immune and physiological characteristics that influence the manifestation of these diseases. In the case of rheumatoid arthritis (RA), a chronic inflammatory disease that affects the joints, treatments that improve functionality and reduce pain in the hands, evaluated by ultrasound, are studied.

Its objective is to compare the effects of treatment with subcutaneous polyvidone collagen versus placebo on clinical improvement of the hands, biochemical response and quality of life in people over 60 years of age with rheumatoid arthritis.

A Phase IV, double-blind, randomized, placebo-controlled clinical trial will be conducted between August 2023 and August 2026. Sixty patients (30 in each group) with early-stage arthritis will participate. Pain, functionality, synovitis, and quality of life will be assessed using various scales, biochemical analyses, and statistical tests.

Eligibility Criteria:
Inclusion Criteria:

* Patients with arthritic hand uni or bilateral
* Early rheumatoid arthritis (\> or equal to 2 years of evolution with treatment and stable)
* Conventional treatment based on non-steroidal anti-inflammatory drugs (NSAIDs) alone for the disease without the use of biologic therapy or DMARDs.

Exclusion Criteria:

* Patient with previous treatment of the arthritic hand with steroids, previous surgery and/or some other local medical treatment
* Persistence of symptoms and functional alterations.
* Patients with diabetes mellitus, rheumatic polyarthropathy, scleroderma, fibromyalgia, systemic lupus erythematosus or any other autoimmune disease.
Endoscopic Retrograde Cholangiopancreatography(ERCP)-Related Discussion Through a Mobile Social App by a Group of Doctors

Group chat through the platform of mobile social networking provides an easily accessible, real-time and interactive channel for communication. With the help of mobile social app, a group of doctors with similar interests can share valuable cases, important papers and opinions through multiple media types (texts, images, and videos). It remains unknown what activities of Endoscopic Retrograde Cholangiopancreatography(ERCP) doctors on a group-chat platform are.

In the beginning of 2013, a chatting group on Wechat (the most popular mobile social app in China), focusing on ERCP, was created. All the doctors who received and finished their ERCP training in Xijing Hospital of Digestive Diseases were invited to join in the platform. The contents in the chatting group were analyzed. The relationships between the chatting activities of ERCP doctors and the performance of ERCP (such as case volume, cannulation success rate and PEP etc.) were investigated.


Eligibility Criteria:
Inclusion Criteria:

* Doctors who received and finished their ERCP training in Xijing Hospital of Digestive Diseases and joined in a chatting group in a mobile social app (Wechat).

Exclusion Criteria:

* Unable to join in the chatting group
* Unable to finish the questionaire
* Denying participating in the study
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

RATIONALE: Dalteparin may be effective in inhibiting the growth of blood vessels in tumors, decreasing the risk of metastatic cancer, preventing the formation of blood clots, and improving quality of life in treating patients with advanced cancer that has not responded to previous treatment. It is not yet known if standard therapy is more effective with or without dalteparin in treating advanced breast, lung, colorectal, and prostate cancer.

PURPOSE: Randomized double blinded phase III trial to compare the effectiveness of standard therapy with or without dalteparin in treating patients who have advanced breast, lung, colorectal, or prostate cancer that has not responded to previous chemotherapy or hormone therapy.

OBJECTIVES: I. Compare the effect of low molecular weight heparin (dalteparin) plus standard therapy versus standard therapy alone on the overall survival rate of patients with advanced cancers. II. Compare the toxic effects of these regimens and the effect on the quality of life of these patients. III. Assess the incidence of symptomatic thrombotic events such as deep venous thrombosis (DVT), pulmonary embolus (PE), and clotted catheters in these patients.

OUTLINE: This is a randomized study. Patients are stratified according to prognostic index (good vs bad vs unsure), current therapy (systemic vs radiation vs both vs none), age (50 or under vs over 50), disease site (breast vs colon vs small cell lung vs nonsmall cell lung vs prostate), history of prior thrombotic event over 1 year ago (yes vs no), and gender. Patients are randomized to receive low molecular weight heparin (dalteparin) plus standard therapy or standard therapy alone.

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically proven breast, lung, colorectal, or prostate cancer that has failed prior chemotherapy or hormone therapy No active CNS metastases Hormone receptor status: Not specified

PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Not specified Performance status: ECOG 0-2 Life expectancy: At least 12 weeks Hematopoietic: WBC at least 3500/mm3 Platelet count at least 150,000/mm3 Fibrinogen above lower limits of normal Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater than 3 times ULN Prothrombin time no greater than 1.5 times ULN Active partial thromboplastin time no greater than 1.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Other: No history of heparin associated thrombocytopenia At least 1 year since prior thromboembolic phenomenon such as deep venous thrombosis, pulmonary embolus, or clotted catheter No prior intolerance of unfractionated or low molecular weight heparin

PRIOR CONCURRENT THERAPY: No concurrent anticoagulation therapy No concurrent enrollment on systemic or radiation therapy study (therapy off study allowed)
Gender Differences in Parkinsonian Patients- a Swedish Register Study

BACKGROUND: The complex impact of gender has been studied in different perspectives of health and disease in the literature. However, few attempts have been made to compile data from systematic disease specific registrations Swedish National Quality Registers play an important role in collecting large amounts of diagnose specific data, symptoms, and treatments. The subset Parkinson Registry has been in use for more than 20 years and are represented in all counties and hospitals where neurological care is provided in Sweden and offer optimal conditions to describe gender specific differences in the use of diagnostic tools, lead times and symptom profiles.

Aim: To study differences between gender in diagnostic tools, pharmacological interventions, and self-reported symptoms in Parkinson´s Disease (PD).

METHODS:

Data were extracted from the Swedish Neuro Registers, one of the Swedish National Quality Registers. A mix of urban and rural parts of the country were chosen and data were divided by gender. Self-reported first experienced PD related symptom was used to define the starting point when processing the data. Zero to three years from this point was defined as early symptoms and over three years as late symptoms.

CONCLUSION:

Differences between gender were seen in all chosen aspects, both diagnostically. Distinctions were also prominent in reported NonMotorSymptoms (NMS) profiles. These findings should be important to take into consideration for patients, professional staff, and caregivers in the daily work with gender mixed PD groups.

Eligibility Criteria:
Inclusion Criteria:

* Participants registered in the Swedish Neuro Registers.
* Parkinson´s Disease
* Acceptance of extraction of data

Exclusion Criteria:

* non parkinsonian patients
* Participants in the Registries who have not given allowance of extraction of data.
Importance of the Infusion Rate for the Plasma Expanding Effect of 5% Albumin in the Septic Patient

Correction of hypovolemia is an important therapeutic measure，Even though there is no consensus regarding infusion rates, a plasma volume (PV) expander is often given at a fast rate to treat a suspected hypovolemia without delay which can be associated with aggravation of adverse interstitial accumulation of macromolecules and fluid, especially in inflammatory conditions such as sepsis.the smallest possible volumes for PV resuscitation to maintain normovolemia should be used to reduce the risk of simultaneous interstitial fluid accumulation. The investigators tested the hypothesis that a slow infusion rate of a PV expander results in better plasma expansion than a fast infusion rate to patients with severe sepsis or septic shock.


Eligibility Criteria:
Inclusion Criteria:

* admitted to the ICU patients with severe sepsis or septic shock (diagnosis according to the 2012 surviving sepsis campaign guidelines)
* there is low blood pressure (SBP \< 90 or mean arterial pressure(MAP) \< 65 or the systolic blood pressure is decreased 40 mmHg more than the basic level) or lactic acid or greater for 4 mmol/l
* the informed consent

Exclusion Criteria:

* less than 18 years of age
* more than 80 years old
* pregnant women
* albumin allergies
* the dying patients expected lifetime no more than 24 hours)
* patient with myocardial infarction, heart failure
* liver failure
* refused to sign the informed consent
Fractional Co2 Laser Versus Microbotox Injection in the Treatment of Wide Facial Pores: A Split Face Comparative Study

1. Evaluation of fractional Co2 laser as a treatment option for wide pores in skin type (III - VI)
2. Evaluation of mesobotox as a new modality for improving wide pores appearance.
3. Comparison of both treatment modalities in treatment of enlarged pores.

Skin pores (SP), as they are called by laymen, are common and benign features mostly located on the face (nose, cheeks, etc) that generate many aesthetic concerns or complaints.

Enlarged skin pores refer to conditions that present with visible topographic changes of skin surfaces. Although not a medical concern, enlarged pores are a cosmetic concern for a large number of individuals.

Enlarged facial pores affect individuals of different ages, sexes, and races for which many seek treatment. The exact patho-mechanism of enlarged facial pores is not completely understood. Possible causes include genetic predisposition, seborrhea, aging, increased ultraviolet exposure and comedogenic products.

The treatment of dilated facial pores is difficult, and the ideal modality is not established yet. Many treatment modalities reduce facial pores' count and area, including oral and topical medications as well as different wavelengths of laser. Different ablative and non ablative lasers have been used in the treatment of dilated pores with variable outcomes.

The short-term results showed that treatment with low energy level CO2 fractional laser therapy could be a safe and effective option for patients with Fitzpatrick skin Types III and IV who are concerned with enlarged pores.

Microbotox also called mesobotox, is the injection of multiple microdroplets of diluted onabotulinum toxin A into the upper dermis. It has been previously used in study to decrease pore size and to improve skin texture.

Microbotox has been proved to be effective in improving the sheen and texture of the skin, as well as decreasing sweat and sebum production and enlarged pores as it causes atrophy of sebaceous glands, which subsequently causes tightening of the skin envelope.

Eligibility Criteria:
Inclusion Criteria:

1. Patient with wide facial pores any grade.
2. Sex: male and female patient.
3. Age groups: patient above 18 and below 45 years old.
4. Co-operative patient.

Exclusion Criteria:

1. Patient below 18 and above 45 years old.
2. Patient with systemic illness or other dermatological disease.
3. Patient who receive topical treatment for facial wide pores in past month.
4. Patient who receive systemic treatment for facial wide pores in past 2 month.
Impact of Nesiritide on Early Postoperative Recovery After Total Cavo-Pulmonary Connection Surgery in Children

Nesiritide, a recombinant human B-type natriuretic peptide, has favorable effects on patient symptoms, hemodynamics, and the neurohumoral profile in adults with decompensated congestive heart failure and in those recovering from cardiac surgery involving cardiopulmonary bypass. Investigators seek to determine whether nesiritide would improve the early postoperative course after total cavo-pulmonary connection surgery in children.

Objective: This study aims to evaluate the efficacy and safety of nesiritide after total cavo-pulmonary connection surgery in children. Investigators hypothesized that compared with placebo, patients assigned to receive nesiritide will improve early postoperative outcomes. Study design: The study is a a single-center, randomized, single-blinded, placebo-controlled, two-arm parallel-group clinical trial, patients undergoing total cavo-pulmonary connection surgery are assigned to receive nesiritide or placebo. A standard dose of study drug was administered by a continuous infusion for ≥24 hours and ≤7 days after cardiac intensive care unit admission. The primary outcome is days of chest drainage. Secondary outcomes included days of hospitalization measures of cardiovascular function, renal function, and adverse events and neurohumoral. The eligible participants will be allocated into intervention and control groups in a 1:1 ratio randomly. The intervention group will receive study drug. All the participants will be followed up during hospitalization .

Statistical analysis: Evaluation will be carried out on an intention-to-treat basis. Values of analyzed endpoints between intervention group and control group will be compared according to the analysis plan.

Eligibility Criteria:
Inclusion Criteria:

1. Elective general anesthesia down Fontan surgery patients, postoperative retention of patients with thoracic drainage tube
2. Age ≤ 14 years old between hospitalized patients, men and women are not limited
3. Postoperative hospital stay\> 7 days
4. Patients or guardians voluntarily signed informed consent

Exclusion Criteria:

1. Before the group had serious head trauma need hospitalization or brain surgery patients
2. Who received organ transplants
3. Preoperative 48 hours application of recombinant B-type natriuretic peptide drugs
4. Preoperative cardiogenic shock or hypotension difficult to correct the patient
5. Preoperative patients with active arrhythmia
6. Preoperative serum creatinine\> 1.5mg / dl or need dialysis patients
7. Preoperative liver dysfunction (glutamic oxalacetic transaminase /glutamic pyruvate transaminase elevated normal high 3 times or more)
8. Failed Fontan patients requiring secondary surgery
9. Patients with allergic to Nesiritide
10. The researchers believe that should not participate in the entry of patients
11. 3 months before the trial participated in other clinical trials
Enhance Wellness for Individuals With Long-Term Physical Disabilities

This project is an adaptation trial, testing the efficacy of an evidence-based community wellness program, Enhance Wellness (http://www.projectenhance.org/enhancewellness.aspx), in a sample of middle and older-aged adults living with multiple sclerosis, spinal cord injury, post-polio syndrome and muscular dystrophy.

This is a quasi-experimental project, comparing the effects of Enhance Wellness in a sample of adults aged 45 years or older and living with long-term physical disability, to two quasi-control groups: a sample of adults without long-term disability participating in Enhance Wellness, and a sample of adults with long-term disability not participating in Enhance Wellness. Outcomes are collected pre-intervention and post-intervention, approximately 6-months apart.

Eligibility Criteria:
Inclusion Criteria:

* Multiple Sclerosis, Muscular Dystrophy, Post-Polio Syndrome, or Spinal Cord Injury diagnosis (Group 1 and 3)
* Living in King County, Washington (Group 1 only)
* Ability to read and understand English

Exclusion Criteria:

* Active suicidal ideation
* Requires the use of a mechanical ventilator to breathe or speak
Safety Study of Intracranial Support Catheter and Guide Catheter for Stent-Assisted Embolization in the Treatment of Intracranial Aneurysms

The purpose of this study is to evaluate the safety differences between intracranial support catheter and guide catheter for stent-assisted embolization in the treatment of unruptured intracranial aneurysms in the anterior circulation.

This is a prospective, multicenter, randomized, open, controlled, superiority trial carried out in 9 research centers over China. Patients are randomized 1:1 to therapy either intracranial support catheter or guide catheter. Taking the guide catheter as a control, to evaluate whether the safety of intracranial support catheter for stent-assisted embolization in the treatment of unruptured intracranial aneurysms in the anterior circulation is superior than that of the control.

Eligibility Criteria:
Inclusion Criteria:

* Age≥18 and≤70 years, any gender;
* Preoperative modified Rankin Scale (mRS) score 0-2;
* Subject has an unruptured intracranial aneurysm in the anterior circulation diagnosed by DSA/CTA/MRA (accept the results from other hospital)；
* No intracranial hemorrhage and recent cerebral infarction (DWI indicates hyperintense lesions) are founded by preoperative MRI+DWI;
* Subject is assessed as suitable for stent-assisted coil embolization (SACE) treatment (except flow diverter stent);
* Subject or guardian is able to understand the purpose of study, shows sufficient compliance with the study protocol and provides a signed informed consent form.

Exclusion Criteria:

* Inadequate antiplatelet therapy before surgery (more than 3 days);
* Subject with atrial fibrillation, patent foramen ovale, atrial septal defect, ventricular septal defect, and other diseases causing cardiogenic embolism;
* Inability to perform cranial MRI+DWI preoperatively and within 48 hours postoperatively;
* Hypertension that does not respond well to medical treatment (systolic blood pressure\>185 mmHg and/or diastolic blood pressure\>110 mmHg);
* Preoperative active bleeding or bleeding tendency (INR\>3);
* Random blood glucose\<2.7mmol/L or \>22.2mmol/L;
* Heart, lung, liver and kidney failure or other serious diseases (intracranial tumor, intracranial arteriovenous malformation, severe infection, DIC, previous myocardial infarction, history of severe psychosis, etc.);
* Subject who will not cooperate or tolerate interventional operation;
* Anticipated life expectancy\<1 year;
* Allergy, resistance or contraindication to one or more of the following: contrast agents, anesthetics, antiplatelet drugs, anticoagulants;
* Participated or participating in another drug or device clinical trial within 1 month prior to enrollment;
* Pregnant or breast-feeding woman;
* Other circumstances judged by researchers that are not suitable for enrollment;
* Catheter could not pass through due to obvious intracranial vessel stenosis or tortuosity determined from imaging;
* Multiple aneurysms and more than one aneurysm requiring treatment;
* The aneurysm body has arterial branches.
Evaluating the Usefulness of 18F-AlF-FAPI PET/ CT in Orbital Neoplasms

To evaluate the potential usefulness of 18F-AlF-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in orbital neoplasms, and compared with 18F-FDG PET/CT.

Subjects with orbital neoplasms underwent contemporaneous 18F-AlF-FAPI and 18F-FDG PET/CT for initial assessment. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The numbers of metastatic lesions of 18F-FDG and 18F-AlF-FAPI PET/CT were recorded by visual interpretation. The sensitivity, specificity, and accuracy of 18F-AlF-FAPI, 18F-FDG PET/CT were calculated and compared to evaluate the diagnostic accuracy.

Eligibility Criteria:
Inclusion Criteria:

1. patients with suspected or newly diagnosed orbital neoplasms (supporting evidence may include MRI, CT and pathology report);
2. patients who had scheduled both 18F-FDG and 18F-AlF-FAPI PET/CT scans;
3. patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

1. patients with pregnancy;
2. breastfeeding;
3. the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.